SciELO - Scientific Electronic Library Online

 
vol.33Establecimiento del esquema de purificación de los antígenos de SOBERANA®02, SOBERANA®Plus y SOBERANA 01Capacidad de procesamiento de los nanofiltros empleados en la purificación de la proteína recombinante del dominio de unión al receptor del coronavirus tipo 2 del síndrome respiratorio agudo severo índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Vaccimonitor

versão On-line ISSN 1025-0298

Resumo

AMIN-BLANCO, Nevis et al. Health intervention with SOBERANA®02 and SOBERANA®Plus vaccines in workers: a successful response in confronting the COVID-19 pandemic. Vaccimonitor [online]. 2024, vol.33  Epub 01-Dez-2024. ISSN 1025-0298.

Vaccination is a way to help protect people by reducing the risk of serious effects from COVID-19 illness. By March of 2021, in record time, Cuba’s biotech industry had five vaccine candidates. A sanitary intervention with a heterologous scheme, two doses of SOBERANA®02 and one dose of SOBERANA®Plus, was carried out in workers during the period of March to June 2021 at Finlay Vaccine Institute, in Havana, Cuba. We evaluated the direct and indirect effects of vaccination with SOBERANA®02 and SOBERANA®Plus, in a cohort at risk of infection, disease and spread of the epidemic COVID-19. The cohort was established in March 2021, among workers with high exposure to SARS-CoV-2, at the area of medical consultation at Finlay Vaccine Institute, established as clinical site. Between March 22, 2021 and June 11, 2021, were enrolled a total of 1,776 participants and, of them, 1,719 met the inclusion criteria with a percentage of 96.79% for first dose, of which 1,675 received the second dose and 1,653 received SOBERANA®Plus as third dose for 97.87%. The majority of participants were aged 19-59 years (1,457), being female, the predominant sex. Among the participants, 175 had adverse events, predominantly observed one hour after the administration of each dose. The most common local reaction was injection site pain. Few unsolicited adverse events were recorded. No vaccine-associated severe or serious adverse events were reported. The distribution of COVID-19 case was 30 post first dose, 16 post second dose and 6 post last dose. No deaths associated with COVID-19 were reported. SOBERANA®02 and SOBERANA®Plus vaccines had a good safety profile and were capable of a reduction of severe COVID-19 illness and death helping to reverse the epidemiological situation caused by the SARS-COV-2 in Cuba.

Palavras-chave : COVID-19; vaccines; workers.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )